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Abstract
Background Bronchodilators are used for managing the
symptoms of chronic obstructive pulmonary disease
(COPD) and minimizing the risk of hospitalization and
readmission. Hospital readmission is predictive of mor-
bidity and mortality.
Objective The study objective was to compare all-cause
readmission risk in COPD patients receiving nebulized
long-acting b2-agonists (neb-LABAs) versus nebulized
short-acting b2-agonists (neb-SABA) following COPD-re-
lated hospitalization discharge.
Methods This retrospective analysis utilized US-based
pharmacy and medical claims records (2001–2011) to
identify COPD patients aged C40 years receiving neb-
LABA or neb-SABA treatment within 30 days following
discharge from a COPD-related hospitalization. Patients
had to be continuously enrolled in their health plan for
C6 months before and after their first neb-LABA or neb-
SABA prescription fill (index date), and adherent to the
treatment for the first 3 months post-index date. To select
patients with similar severity profiles, neb-LABA and neb-
SABA patients were matched by baseline characteristics.
Readmission risks were observed over the 6-month period
following the index date and compared between neb-
LABA and neb-SABA cohorts using the multiple variable
Cox proportional hazards model.
Results The analysis included 246 matched patients (neb-
LABA = 123; neb-SABA = 123). The mean age was
67 years, and 54% were female. The average length of stay
during index hospitalization was 4.4 days. After adjusting
for potential confounders, the risk of readmission was 47%
lower in the neb-LABA cohort than in the neb-SABA
cohort (hazard ratio 0.53, 95% confidence interval
0.30–0.96; P = 0.0349).
Conclusions Patients receiving neb-LABAs had a signifi-
cantly lower readmission risk within 6 months following a
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Key Points
Hospital readmissions are associated with increased
morbidity and mortality risk in patients with chronic
obstructive pulmonary disease (COPD). Minimizing
readmissions is therefore a key management goal for
COPD. Despite guideline recommendations for use of
long-acting bronchodilator therapy for maintenance
treatment of COPD, some patients continue to receive
only short-acting bronchodilator therapy even after a
COPD-related hospitalization event.
Patients who received nebulized long-acting b2-
agonists following COPD-related hospitalization
discharge were found to have a 47% lower risk of
readmission compared with patients who received
nebulized short-acting b2-agonists.
Our study adds evidence to the effectiveness of
nebulized long-acting b2-agonists versus short-acting
b2-agonists for the chronic management of COPD
symptoms. The results of our study highlight the
importance of appropriate maintenance therapy for
symptom control and prevention of COPD
exacerbations.
1 Introduction
Chronic obstructive pulmonary disease (COPD) is a pro-
gressive disease characterized by persistent airflow limi-
tations, dyspnea, cough, and sputum production, and is
often complicated by exacerbations, resulting in chronic
inflammation of the respiratory system [1]. COPD is a
leading cause of morbidity and mortality worldwide [2]. It
accounted for 40.8 deaths per 100,000 persons in the USA
in 2010 and is ranked as the third most common cause of
death [2]. COPD is the second highest contributing factor
to the risk of living with a disability in the USA [1, 3, 4].
Although there is currently no cure for COPD, it is
treatable, and exacerbations leading to hospitalizations
and readmissions are preventable [5–7]. Minimizing
COPD-related hospital readmission is an important goal
in the management of COPD as the readmission rates are
predictive of morbidity and mortality [8]. Costs associated
with COPD hospital readmission are staggering,
amounting to over $1 billion (USD 2013) per annum in
the USA [9].
Although many treatments can be considered in the
management of COPD (e.g., b2-agonists, anticholinergics,
corticosteroids, combination therapies) [5, 10–12], bron-
chodilators, specifically short-acting b2-agonists (SABAs)
and long-acting b2-agonists (LABAs), are the mainstay of
treatment in COPD patients to improve lung function and
manage COPD symptoms [6]. Long-acting bronchodilators
are recommended for maintenance treatment while short-
acting bronchodilators are recommended as rescue medi-
cations for moderate-to-severe COPD patients [1, 5, 13].
However, despite guideline recommendations, some
patients receive only SABA treatment as the primary
maintenance therapy, even after a COPD-related hospital-
ization [14–16].
COPD inhalation treatments, including LABAs and
SABAs, are primarily delivered through one of the fol-
lowing three mechanisms: pressurized metered-dose
inhalers (pMDIs), dry powder inhalers (DPIs), or nebu-
lizers [17, 18]. Despite comparable efficacies of the
devices [17, 19], user errors are common with pMDIs and
DPIs [18–20], resulting in inadequate medication dosing
with subsequent suboptimal symptom control and an
increased rate of exacerbations and hospitalizations
[18, 20–24]. Accordingly, for some patients, COPD
management may be improved with the use of nebulizers
for maintenance therapy administration. In clinical prac-
tice, nebulizers are generally used in elderly patients, in
patients with physical or cognitive limitations, or in
patients with severe disease and frequent exacerbations
[19].
Few studies have examined the role of LABA or SABA
treatments delivered through a nebulizer, in general, on the
readmission risk for patients with COPD. One study
demonstrated treatment with nebulized arformoterol during
an initial COPD-related hospitalization was associated with
a lower 30-day readmission rate compared with treatment
with nebulized SABA [25].
The aim of the current study was to compare the read-
mission risk within 6 months following discharge from a
COPD-related hospitalization in patients with COPD




This retrospective observational study used data from the
PharMetrics Integrated Claims Database from January
2001 to December 2011. The PharMetrics database con-
tains comprehensive medical and pharmacy claims data for
more than 70 million members from over 100 healthcare
plans across the USA [26]. It includes information about
patient demographics, duration of healthcare plan enroll-
ment, inpatient and outpatient diagnoses and procedures,
and pharmacy prescription dispensing claims [26]. Data are
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de-identified and comply with the Health Insurance
Portability and Accountability Act.
2.2 Study Design
A matched cohort design was used for this study. The
baseline period was defined as the 6-month period prior to
the first neb-LABA or neb-SABA prescription fill index
date. The study period spanned from the index date to
6 months following the index date (Fig. 1).
2.3 Sample and Cohort Selection
Patients with a COPD-related hospitalization were selected
from the PharMetrics database. A COPD-related hospital-
ization was defined as (i) a hospitalization with a primary
diagnosis for COPD (ICD-9-CM code: 491.xx, 492.xx,
496.xx) or (ii) a hospitalization with a secondary diagnosis
for COPD and a primary diagnosis for another respiratory-
related disease (ICD-9-CM code: 460.xx to 519.xx—ex-
cluding 491.xx, 492.xx and 496.xx). Selected patients had
to receive a neb-LABA (arformoterol or formoterol) or a
neb-SABA (albuterol or albuterol ? ipratropium or leval-
buterol) within 30 days following the discharge date of the
index hospitalization. Only LABA and SABA treatments
that were available in a nebulizer formulation during the
period covered by the data (2001–2011) were included in
this study. In addition, patients were required to be con-
tinuously enrolled in a healthcare plan at least 6 months
prior to and at least 6 months after the first prescription fill
for a neb-LABA or neb-SABA, and 40 years of age or
older at the index date. The first medication (neb-LABA or
neb-SABA) prescribed after discharge of the index hospi-
talization and the first fill date were defined as the index
treatment and index date, respectively.
Given that there is no information in claims data on
reasons for treatment initiation, we could not confirm
whether neb-SABA was being used as a rescue medication
for these patients. As an attempt to identify patients initi-
ated on maintenance therapy (as opposed to patients using
neb-LABA or neb-SABA on an ‘‘as-needed’’ basis),
patients were required to meet the following minimum
treatment duration requirement during the first 3 months
following the index date: a proportion of days covered
(PDC) by the index treatment of at least 50% [27–29], or at
least two prescriptions for the index treatment. The PDC is
calculated as the sum of the days covered by the index
treatment divided by the number of calendar days in the
specified measurement period (i.e., 3 months post-index
date) [30–32], which avoids the potential issue of counting
twice when there is an overlap between refills or an over-
supply of medication [33]. Patients were excluded from the
study if they had an index hospitalization stay that lasted
C30 days to avoid inclusion of atypical patient profiles that
may be associated with abnormally long hospitalizations.
From the sample of patients satisfying the selection
criteria described above, patients were divided into two
mutually exclusive cohorts based on their index treatment.
The neb-LABA cohort contained patients whose index
medication was a neb-LABA, and the neb-SABA cohort
contained patients whose index medication was a neb-
SABA. Since patients receiving neb-LABA treatments may




SABA nebulized short-acting b2-
agonist
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use neb-SABA treatments occasionally as rescue medica-
tion, patients who received both neb-LABA and neb-
SABA treatments were included in the neb-LABA cohort.
Given that this is a retrospective observational non-ran-
domized cohort study, as an attempt to balance disease
severity profiles between cohorts, a matching technique
was used to identify a subgroup of neb-SABA patients who
had characteristics that were generally similar to those of
the neb-LABA patients. Each neb-LABA patient was
matched to a neb-SABA patient using a combination of
exact matching and matching within calipers based on age,
gender, length of index hospitalization, specialist encoun-
ters at the index date, number of days between the index
hospitalization discharge and the index date, and COPD-
related pharmacy and medical service costs during the
6-months prior to the index date. A range of values was
allowed in certain categories on the basis of which the
patient matching was performed: ±2 years for age,
±2 days for the length of a hospital stay, ±5 days between
the index hospitalization discharge and the index date,
±$500 for drug costs, and ±$200 for total medical service
costs. Prior to matching, the patient cohorts were desig-
nated as the pre-match sample; after patient matching was
performed, the resulting cohorts were designated as the
post-match sample.
2.4 Measures and Outcomes
2.4.1 Patient Baseline Characteristics
Baseline characteristics included demographics (age, gen-
der, geographic region), characteristics of index hospital-
ization (respiratory complications during the index
hospitalization, length of the index hospitalization), char-
acteristics of COPD treatment (specialty physician pre-
scribing the index neb-LABA or neb-SABA, days between
index hospitalization and the index date, Deyo-Quan
Charlson Comorbidity Index) [34, 35], total healthcare
costs at baseline (including pharmacy costs, COPD-related
pharmacy costs, medical services costs, and COPD-related
medical services costs), and healthcare resource utilization
(HRU; comprising hospitalizations, emergency room visits,
and outpatient visits).
2.4.2 Readmission
Patients were observed from the index date up to the first
all-cause readmission or the end of the study period,
whichever occurred first. A readmission was defined as the
occurrence of a hospitalization during the 6-month study
period (i.e., post-index period), regardless of the diagnosis
associated with the readmission (all-cause).
2.5 Statistical Analysis
Patient baseline characteristics were compared between the
neb-LABA and neb-SABA cohorts using Wilcoxon tests
for continuous variables and chi-square tests for categorical
variables for the pre-match samples and using the McNe-
mar test for categorical variables and the Wilcoxon signed
rank test for continuous variables for the post-match
samples.
The proportion of patients who had at least one read-
mission over the 6-month period after the index date was
compared between the neb-LABA and neb-SABA cohorts
for the post-match samples. Kaplan–Meier analyses were
conducted to illustrate the crude readmission rates over
time for both cohorts for the post-match samples. A mul-
tiple variable regression analysis, adjusting for baseline
confounding factors that remained statistically significant
after the match, was also conducted using Cox propor-
tional-hazards models to evaluate the risk of readmission
associated with either treatment (neb-LABA or neb-
SABA). Results were reported as hazard ratios (HRs) along
with their corresponding 95% confidence intervals (CIs)
and P values. The multiple variable model adjusted for
differences in patient baseline characteristics that remained
statistically significant after the match was performed and
included regions, COPD duration, acute respiratory failure,
outpatient visits, and COPD-related pharmacy costs.
3 Results
3.1 Patient Baseline Characteristics
A total of 201 neb-LABA patients and 13,474 neb-SABA
patients met all the selection criteria; among them, 246
patients were matched (123 per cohort) (Fig. 2).
Before matching, more patients in the neb-LABA cohort
suffered from acute respiratory failure and had a pulmo-
nologist encounter at the index date compared with patients
in the neb-SABA cohort (31.8 vs. 23.1%, P\ 0.0035 and
9.5 vs. 4.3%, P\ 0.0004, respectively). Patients in the
neb-LABA cohort also had higher baseline healthcare costs
and HRU (in particular, hospitalizations and outpatient
visits) compared with patients in the neb-SABA cohort
(Table 1). Neb-LABA users had a longer time between the
index hospitalization discharge date and the index pre-
scription fill date than neb-SABA users (12.37 mean days
vs. 8.31 mean days, P\ 0.0001). In addition, there were
regional differences in the cohort samples: the neb-LABA
cohort had more patients from the eastern region of the
USA; the neb-SABA cohort had more patients from the
Midwest.
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After matching, most differences between cohorts were
nonsignificant with only geographic location, the rate of
acute respiratory failure, and the number of outpatient
visits remaining statistically significant. In the post-match
sample, patients had a mean age of 67 years and were
mostly (54%) female. The length of the index hospital-
ization was 4.4 days, with patients filling their index pre-
scription on average 12 days after discharge. Patients had,
on average, approximately 1.3 hospitalizations, and had
incurred approximately $22,000 (USD 2012) in healthcare
costs during the baseline period.
3.2 Readmission
Approximately 32% of neb-LABA and 38% of neb-SABA
patients had at least one readmission during the 6-month
period following the index date (Table 2). Patients in the
neb-LABA cohort had a longer time to readmission com-
pared with patients in the neb-SABA cohort (Fig. 3). After
adjusting for differences in patient baseline characteristics,
the risk of readmission was found to be 47% lower in the
neb-LABA cohort as compared with the neb-SABA cohort
(HR 0.53; 95% CI 0.30–0.96, P = 0.0349) (Table 2).
4 Discussion
COPD treatments are primarily delivered through pMDIs,
DPIs, or nebulizers [17, 18]. In this study, we evaluated
medications delivered through a nebulizer. While pMDIs
and DPIs are the most widely used devices, some patients
may benefit from a drug delivery through a nebulizer. In
particular, elderly patients, patients with physical or cog-
nitive limitations, or patients with severe disease and fre-
quent exacerbations may benefit from the use of a nebulizer
[19]; the ease of use of nebulizers may alleviate the diffi-
culty with pMDI and DPI techniques, and allow for better
drug delivery in these patients.
While minimizing exacerbations, and thus hospitaliza-
tions and readmission, is an important goal in the man-
agement of COPD, the impact of nebulized LABA or
SABA therapy on risk for readmission remains unclear.
This is especially important because some patients with
moderate-to-severe COPD only receive SABA therapy to
manage their symptoms [16]. In this study, neb-LABAs
were shown to be associated with a significantly lower risk
(by almost half) of readmission, within 6 months following
a COPD-related hospitalization, when compared with neb-
SABAs. This is in line with findings from a previous study
that evaluated readmission risk with nebulized arfor-
moterol versus neb-SABA. The study used a matched case-
control design in patients initiated on nebulized arfor-
moterol or neb-SABA during a COPD-related hospital-
ization [25]. The unadjusted and adjusted all-cause 30-day
readmission rates were lower in patients receiving nebu-
lized arformoterol compared with patients receiving neb-
SABA despite neb-LABA patients having indicators of
more severe disease at baseline. The odds of being read-
mitted were also lower for the arformoterol group [25].
SABAs have a faster onset and shorter duration (4–6 h)
of action compared with LABAs, thus they are suited for
rapid control of acute COPD symptoms. SABAs are cur-
rently recommended as rescue medications for COPD
treatment to be used on an ‘‘as-needed’’ basis, while
Fig. 2 Study sample selection. COPD chronic obstructive pulmonary
disease, neb-LABA nebulized long-acting b2-agonist, neb-SABA
nebulized short-acting b2-agonist, PDC proportion of days covered.
aPatients who met the selection criteria to qualify for both cohorts
were included in the neb-LABA cohort only
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LABAs have been shown to offer better symptom control
and more convenient use (every 12 or 24 h in the case of
‘‘ultra-long-acting’’ agents), and so are recommended as
maintenance treatment for all stages of COPD, except for
mild stage [1, 5, 13]. However, despite guideline recom-
mendations, some patients use SABAs on a regular basis as
primary maintenance therapy even after a severe exacer-
bation. Findings from the current study suggest that
Table 1 Patient baseline characteristics











Age, years, mean ± SD 67.43 ± 11.27 67.12 ± 12.44 0.4755 67.59 ± 10.40 67.31 ± 9.99 0.3206
Female, n (%) 120 (59.7) 7486 (55.6) 0.2406 66 (53.7) 66 (53.7) 1.0000
Region, n (%)
East 65 (32.3) 2991 (22.2) 0.0006 44 (35.8) 26 (21.1) 0.0027
South 57 (28.4) 3749 (27.8) 0.8668 39 (31.7) 34 (27.6) 0.4349
Midwest 60 (29.9) 5367 (39.8) 0.0041 30 (24.4) 51 (41.5) 0.0027
West 19 (9.5) 1367 (10.1) 0.7467 10 (8.1) 12 (9.8) 0.6698
Characteristics of index hospitalization and specialist encounters
Respiratory complications during the index hospitalization, n (%)
Acute respiratory failure 64 (31.8) 3111 (23.1) 0.0035 38 (30.9) 21 (17.1) 0.0095
Respiratory arrest 10 (5.0) 1042 (7.7) 0.1452 6 (4.9) 7 (5.7) 0.763
Dyspnea 149 (74.1) 9445 (70.1) 0.215 88 (71.5) 85 (69.1) 0.6744
Viral/bacterial pneumonia 84 (41.8) 5925 (44.0) 0.536 48 (39.0) 48 (39.0) 1.0000
Influenza 2 (1.0) 235 (1.7) 0.4192 1 (0.8) 1 (0.8) 1.0000
Other acute respiratory infections 24 (11.9) 2069 (15.4) 0.1819 18 (14.6) 18 (14.6) 1.0000
Length of the index hospitalization, days,
mean ± SD
5.48 ± 4.52 5.31 ± 4.33 0.5292 4.37 ± 2.69 4.40 ± 2.51 0.9367
Days between index hospitalization
discharge and the index date, mean ± SD
12.37 ± 9.28 8.31 ± 9.27 \0.0001 12.08 ± 9.06 11.96 ± 9.27 0.6673
Pulmonologist encounter, n (%) 19 (9.5) 577 (4.3) 0.0004 3 (2.4) 3 (2.4) 1.0000
Charlson Comorbidity Index, mean ± SD 2.57 ± 1.69 2.55 ± 1.80 0.5196 2.30 ± 1.55 2.51 ± 1.79 0.2934
Total healthcare costs at baseline, USD
2012, mean ± SD
32,130 ± 31,049 26,185 ± 38,139 \0.0001 22,191 ± 18,253 21,974 ± 18,619 0.5860
Pharmacy costs 4556 ± 4623 2558 ± 3761 \0.0001 3332 ± 2728 3153 ± 2511 0.7254
Medical services costs 27,575 ± 29,560 23,627 ± 37,338 \0.0001 18,859 ± 18,152 18,821 ± 18,352 0.6086
Healthcare resources utilization at baseline, mean ± SD
Hospitalizations 1.49 ± 0.86 1.38 ± 0.79 0.0438 1.34 ± 0.69 1.40 ± 0.88 0.6166
Emergency room visits 0.77 ± 1.13 0.73 ± 1.70 0.0989 0.74 ± 1.15 0.60 ± 1.21 0.1206
Outpatient visits 13.00 ± 10.33 10.95 ± 10.03 0.0002 12.50 ± 10.51 10.11 ± 8.27 0.0165
neb-LABA nebulized long-acting b2-agonist, neb-SABA nebulized short-acting b2-agonist, SD standard deviation, USD US dollars




Readmission 39 (31.7) 47 (38.2) 0.53 (0.30–0.96) 0.0349b
CI confidence interval, neb-LABA nebulized long-acting b2-agonist, neb-SABA nebulized short-acting b2-
agonist
a A hazard ratio\1 indicates that patients in the neb-LABA cohort had a lower risk of experiencing a
readmission than patients in the neb-SABA cohort
b Significant at the 5% level
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patients who received neb-SABA as maintenance therapy
following a COPD-related hospitalization discharge could
benefit from LABA treatment to reduce the risk of hospital
readmission. Since the lack of (or improper) treatment may
lead to disease exacerbations [1, 5], which, in turn, increase
the risk of morbidity and mortality and constitute a sig-
nificant burden on the patient [16, 36], the use of an
appropriate pharmacologic agent (e.g., LABA) for the
maintenance of symptom control and prevention of exac-
erbations of COPD cannot be overemphasized. However,
further studies are warranted to understand the physicians’
rationale for prescribing neb-SABA versus neb-LABA
treatment after a COPD-related hospitalization.
4.1 Limitations
This study is subject to the common limitations of retro-
spective, observational studies based on healthcare claims
data, such as data omission or coding errors. However,
these errors are expected to affect the two cohorts to a
similar extent and are unlikely to change the conclusions.
Second, claims databases record diagnostic and procedural
codes only and do not indicate disease severity. The
severity of COPD symptoms varies among individuals and
might affect a patient’s treatment profile. However, since
clinical assessments of severity were not available, we used
a matched cohort design to select patients with likely
similar severity profiles based on different proxies of
severity. Nevertheless, unobservable differences in severity
may remain. If such differences in severity exist, we would
expect the neb-LABA patients to be the most severe
cohort; therefore, we are likely to underestimate the dif-
ference between the two cohorts. Nonetheless, claims data
remain a valuable source of information, as they comprise
a valid and large sample and have the advantage of
reflecting patients’ behavior in a real-world setting. Third,
patients who received a neb-LABA and neb-SABA therapy
concomitantly following the index hospitalization were
included in the neb-LABA cohort. Accordingly, by design
it was not possible for a patient in the neb-SABA cohort to
concomitantly use a neb-LABA. However, no selection
criteria were applied for the other types of SABA and
LABA. Indeed, patients may have used a neb-SABA and
an inhaled LABA concomitantly. No adjustment was made
for the use of other forms of treatment for COPD given that
the use of neb-SABA and neb-LABA is likely to be asso-
ciated with the use of different types of non-nebulized
treatments. Fourth, results from this study reflect outcomes
of COPD patients who received SABA and LABA main-
tenance therapy through nebulizers. However, these results
may not be representative of the overall population of
patients with COPD who received SABA and LABA
therapy delivered through other mechanisms (pMDI, DPI).
Finally, the current study used data from a US claims
database covering the period from 2001 to 2011. Recent
advances in COPD disease management and treatments
may influence outcomes in COPD patients, including
readmission risk following COPD-related hospitalization
discharge. Further research using more recent data would
be warranted to assess readmission in more recent years.
5 Conclusions
Based on a comparison of administrative claims in the
6 months following a COPD-related hospitalization of a
matched population of COPD patients, those who received
neb-LABA following a COPD-related hospitalization dis-
charge were found to have a significantly lower risk of
readmission than that of neb-SABA-treated patients.
Fig. 3 Time to first readmission among patients treated with a neb-LABA and neb-SABA after a COPD exacerbation hospitalization. COPD
chronic obstructive pulmonary disease, neb-LABA nebulized long-acting b2-agonist, neb-SABA nebulized short-acting b2-agonist
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